STAT3 GOF

Clinical trials for STAT3 GOF explained in plain language.

Never miss a new study

Get alerted when new STAT3 GOF trials appear

Sign up with your email to follow new studies for STAT3 GOF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for rare immune disorders: upadacitinib trial launches

Disease control Not yet recruiting

This study tests the drug upadacitinib (Rinvoq) in 30 people with rare genetic disorders that overactivate the JAK-STAT immune pathway. The trial has four phases over 12 months, including an open-label phase to find the best dose and a randomized withdrawal phase to compare the d…

Matched conditions: STAT3 GOF

Phase: PHASE1, PHASE2 • Sponsor: Lisa Satter • Aim: Disease control

Last updated Jul 03, 2026 19:22 UTC

STAT3 GOF

Get alerted when new STAT3 GOF trials appear

New hope for rare immune disorders: upadacitinib trial launches